Despite the success rates of the Pfizer and Moderna vaccines, COVID-19 remains a global threat. Vaccine distribution complications and slow adoption by the public create an opportunity for vaccine-resistant variants to arise. Current treatment practices, including the use of corticosteroids or intravenous immunoglobulin, are supportive, rather than therapeutic. Apart from remdesivir, an RNA-dependent RNA polymerase (RdRP)-inhibitor that inhibits coronaviruses SARS-CoV and MERS-CoV, no drugs have been FDA-approved for use as repurposable therapeutic drugs. There is an urgent need to develop new therapeutics against COVID-19.